Bowside Capital

Advisory Board Member

David M. Mott
Mott Family Capital

Mr. Mott is a private investor through Mott Family Capital.  From September 2008 to February 2020, Mr. Mott was general partner at New Enterprise Associates (“NEA”) and lead the healthcare investing practice.  NEA is among the largest venture capital firms in the world and invests across all stages in technology and healthcare.  Mr. Mott’s personal investing practice was primarily focused on biopharmaceutical investments.

Prior to joining NEA, Mr. Mott was president and chief executive officer of biotechnology company MedImmune.  He joined MedImmune in 1992 and served in various roles, including president and chief executive officer from October 2000 through June 2008 and previously chief financial officer and president and chief operating officer.  Mr. Mott led the sale of MedImmune to AstraZeneca in June 2007 for $15.6 billion.  Earlier in his career, he was a vice president in healthcare investment banking at Smith Barney, Harris Upham & Co., Inc.

Mr. Mott earned a B.A. from Dartmouth College.